Literature DB >> 17214505

Does industry sponsorship undermine the integrity of nutrition research?

Martijn B Katan1.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17214505      PMCID: PMC1761050          DOI: 10.1371/journal.pmed.0040006

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.069


× No keyword cloud information.
The commercial success of foods depends more and more on what science says about the effects of these foods on health. Drug companies have tried to influence the scientific record so as to make their products look healthier [1,2]; are food companies doing the same? In a study published in PLoS Medicine, Lesser et al. [3] investigated this by analyzing 206 publications on the health effects of milk, soft drinks, and fruit juices. Twenty-four of these studies had been funded solely by the industry whose product was investigated, while 52 of the papers declared that they had had no industrial support. The other papers had mixed support or did not declare sponsorship. The odds that a paper would report a favorable outcome were four to eight times higher when the study was funded by the manufacturer of the beverages in question than when the study was not funded by industry. Out of the 35 interventional studies, which included human trials, industry was the sole sponsor of 16, and none of these 16 reported an unfavorable outcome. In contrast, seven of the 19 interventional studies with mixed or no industry funding found an unfavorable effect. Thus, papers sponsored by industry were more likely to report favorable outcomes for that industry's beverages than papers with other sources of funding. The study by Lesser et al. was carefully done, the number of articles was sufficiently large, the analyses were straightforward, and they agree with the outcomes of earlier, smaller studies. However, an association between funding and outcome does not by itself prove bias. First, five of the papers dealt with outbreaks of food poisoning and none of these studies was funded by industry, which strengthened the correlation of unfavorable outcomes with the absence of industry funding. But industry was, of course, never asked to fund these studies and therefore bias was not an issue. Second, when producers plan to fund a nutrition study, they will naturally select a product with a potentially favorable nutritional profile. Drug companies have tried to influence the scientific record so as to make their products look healthier; are food companies doing the same? However, such selection is the start of a slippery slope. When an industry is the major sponsor of research on its own product, unfavorable effects of that product are less likely to be investigated. The next step down the slope is adjustment of designs. The dosage of the product and the nature of control treatments may be adjusted so as to increase the chance that the study will demonstrate benefits of the product or that adverse effects will not reach statistical significance. Also, unfavorable data may be deemed less relevant and may be left out of the abstract and the press release, or out of the paper itself. Finally, the whole publication may be cancelled or seriously delayed when the outcome is disappointing to the sponsor. Innocuous-sounding clauses in the contract may give the company such a veto right, and investigators may not fully realize the consequences of what they are signing. Some contract research organizations grant the sponsor that veto right up front. Even if researchers can legally publish the data, they may be reluctant to antagonize a major sponsor. There are indications that all these things happen [4,5], but there are few hard quantitative data to prove it. As Marion Nestle said in her landmark book [5]: “I could not find anyone who would speak to me ‘on the record’ for this book. When I told friends in government, food companies, and academia that I was writing a book about how the food industry affects nutrition and health, they offered to tell me anything I wanted to know, but not for attribution.” We obviously need more studies of the relations between industry and nutrition research, and they may need to go beyond the data made public in scientific journals. Meanwhile, what should we do? My personal experience makes me reluctant to support a blanket condemnation of industry-supported research, because collaboration with industry has allowed me to discover things that I could not have found otherwise. We discovered the effects of trans fatty acids on heart disease risk [6] thanks to the expertise of Unilever, and the cholesterol-raising factor in unfiltered coffee [7] thanks to Nestlé. But researchers dealing with industry may be subjected to pressure, and they need help to resist such pressure. Most universities now have a code of conduct on relations with industry and conflicts of interest, but when the negotiations come down to the wire, and money and jobs are at stake, then a code of conduct may not be enough to keep a researcher on the straight and narrow. The Royal Netherlands Academy of Sciences has put forth an innovative proposal on how to supervise relations between researchers and their sponsors [8]. For now, the Lesser et al. study raises serious concerns that some food industries may distort the scientific record on diet and health. Such concerns affect nutrition science as a whole, if only because they threaten public confidence in nutrition research, and once that confidence is gone nutrition research becomes irrelevant.
  5 in total

1.  Uneasy alliance--clinical investigators and the pharmaceutical industry.

Authors:  T Bodenheimer
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

Review 2.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

3.  Identity of the cholesterol-raising factor from boiled coffee and its effects on liver function enzymes.

Authors:  M P Weusten-Van der Wouw; M B Katan; R Viani; A C Huggett; R Liardon; R Liardon; P G Lund-Larsen; D S Thelle; I Ahola; A Aro
Journal:  J Lipid Res       Date:  1994-04       Impact factor: 5.922

4.  Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects.

Authors:  R P Mensink; M B Katan
Journal:  N Engl J Med       Date:  1990-08-16       Impact factor: 91.245

5.  Relationship between funding source and conclusion among nutrition-related scientific articles.

Authors:  Lenard I Lesser; Cara B Ebbeling; Merrill Goozner; David Wypij; David S Ludwig
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

  5 in total
  8 in total

1.  Pouring rights contracts between universities and beverage companies: Provisions related to scientific research.

Authors:  Sara E Benjamin-Neelon; Elyse R Grossman; Eva Greenthal; Stephanie A Lucas; Katherine Marx; Martha Ruffin
Journal:  Prev Med Rep       Date:  2022-07-08

Review 2.  Industry funding and the reporting quality of large long-term weight loss trials.

Authors:  O Thomas; L Thabane; J Douketis; R Chu; A O Westfall; D B Allison
Journal:  Int J Obes (Lond)       Date:  2008-08-19       Impact factor: 5.095

3.  PLoS Medicine series on Big Food: the food industry is ripe for scrutiny.

Authors: 
Journal:  PLoS Med       Date:  2012-06-19       Impact factor: 11.069

4.  Funding source and research report quality in nutrition practice-related research.

Authors:  Esther F Myers; J Scott Parrott; Deborah S Cummins; Patricia Splett
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

5.  Causes of metabolic syndrome and obesity-related co-morbidities Part 1: A composite unifying theory review of human-specific co-adaptations to brain energy consumption.

Authors:  Anne-Thea McGill
Journal:  Arch Public Health       Date:  2014-09-01

6.  Capable and credible? Challenging nutrition science.

Authors:  Bart Penders; Anna Wolters; Edith F Feskens; Fred Brouns; Machteld Huber; Els L M Maeckelberghe; Gerjan Navis; Theo Ockhuizen; Jogchum Plat; Jan Sikkema; Marianne Stasse-Wolthuis; Pieter van 't Veer; Marcel Verweij; Jan de Vries
Journal:  Eur J Nutr       Date:  2017-07-17       Impact factor: 5.614

7.  Using risk of bias domains to identify opportunities for improvement in food- and nutrition-related research: An evaluation of research type and design, year of publication, and source of funding.

Authors:  E F Myers; J S Parrott; P Splett; M Chung; D Handu
Journal:  PLoS One       Date:  2018-07-05       Impact factor: 3.240

Review 8.  Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: a systematic review.

Authors:  Mary N Mugambi; Alfred Musekiwa; Martani Lombard; Taryn Young; Reneé Blaauw
Journal:  BMC Med Res Methodol       Date:  2013-11-13       Impact factor: 4.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.